{
    "name": "pramlintide",
    "comment": "Rx",
    "other_names": [
        "Symlin",
        "SymlinPen 120",
        "SymlinPen 60"
    ],
    "classes": [
        "Antidiabetics",
        "Amylinomimetics"
    ],
    "source": "https://reference.medscape.com/drug/symlin-pramlintide-342890",
    "pregnancy": {
        "common": [
            "Available data from a small number of reports in manufacturer’s safety database on use in pregnant women are not sufficient to determine a drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes; there are risks to mother and fetus associated with poorly controlled diabetes in pregnancy",
            "Ex-vivo studies using term perfused human, rabbit, and rat placentas indicate that drug has low potential to cross maternal/fetal placental barrier",
            "Poorly controlled diabetes in pregnancy increases maternal risk for diabetic ketoacidosis, preeclampsia, spontaneous abortions, preterm delivery, and delivery complications; poorly controlled diabetes increases fetal risk for major birth defects, stillbirth, and macrosomia related morbidity"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "In animal reproduction studies, congenital abnormalities were observed in fetuses of pregnant rats but not in fetuses of pregnant rabbits exposed during organogenesis to drug at 10 times clinical dose of 360 mcg/day, based on exposure"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There is no data on presence in human milk, effects on breastfed infant, or on milk production; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for drug and any potential adverse effects on breastfed child from drug or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Pramlintide is used with insulin and has been associated with an increased risk of insulin-induced severe hypoglycemia, particularly in patients with type 1 diabetes",
                "When severe hypoglycemia associated with pramlintide use occurs, it is seen within 3 hours following injection",
                "If severe hypoglycemia occurs while operating a motor vehicle or heavy machinery, or while engaging in other high-risk activities, serious injuries may occur. Appropriate patient selection, careful patient instruction, and insulin dose adjustments are critical elements for reducing this risk"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Confirmed gastroparesis",
                "Hypoglycemia unawareness"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Do not mix with insulin - administer the two separately",
                "Slows gastric emptying, which may delay the absorption of concomitantly administered oral medications; administer the concomitant oral medication at least 1 hr prior to injection or 2 hr after injection if rapid onset or threshold concentration of concomitant medication is a critical determinant of its effectiveness (such as with analgesics, antibiotics, and oral contraceptives)",
                "Slows gastric emptying; not recommended if taking other medications that alter gastrointestinal motility",
                "Never share pen between patients even if needle is changed",
                "Erythema, edema, or pruritus at site of injection reported; may be related to other factors, such as irritants in a skin cleansing agent or improper injection technique"
            ],
            "specific": [
                {
                    "type": "Hypoglycemia",
                    "description": [
                        "Risk of severe insulin-induced hypoglycemia; pramlintide alone does not cause hypoglycemia; however, since it is indicated to be coadministered with mealtime insulin therapy, and in this setting, there is an increased risk of severe hypoglycemia, particularly in patients with type 1 diabetes",
                        "If severe hypoglycemia occurs with therapy, it is usually seen within first 2-3 hr following injection",
                        "If severe hypoglycemia occurs while operating a motor vehicle, heavy machinery, or while engaging in other high-risk activities, serious injuries or death may occur",
                        "When introducing therapy, appropriate precautions need to be taken to avoid increasing risk for severe hypoglycemia; these precautions include frequent monitoring of pre- and post-meal glucose combined with initial 50% reduction in doses of mealtime insulin",
                        "Early warning symptoms of hypoglycemia may be different or less pronounced under certain conditions, such as longstanding diabetes; diabetic neuropathy; use of medications such as beta-blockers, clonidine, guanethidine, or reserpine; or intensified glycemic control",
                        "Addition of any anti-diabetic medication, such as this one, to an existing regimen of one or more anti-diabetic medications (eg, sulfonylurea), or other medications that can increase risk of hypoglycemia may necessitate further insulin dose adjustments and particularly close monitoring of blood glucose"
                    ]
                },
                {
                    "type": "Proper patient selection",
                    "description": [
                        "Proper patient selection is essential to safe and effective use",
                        "For use only in patients with type 1 or type 2 diabetes using mealtime insulin who fulfill the following criteria:",
                        "-failed to achieve adequate glycemic control despite individualized insulin management",
                        "-receiving ongoing care under the guidance of a healthcare professional skilled in the use of insulin and supported by the services of diabetes educator",
                        "Not for use in patients with ANY of the following criteria:",
                        "-poor compliance with current insulin regimen",
                        "-poor compliance with prescribed self blood glucose monitoring",
                        "-have a HbA1c >9%",
                        "-recurrent severe hypoglycemia requiring assistance during the past 6 months",
                        "-presence of hypoglycemia unawareness",
                        "-confirmed diagnosis of gastroparesis",
                        "-require the use of drugs that stimulate gastrointestinal motility",
                        "-pediatric patients"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "insulin aspart",
            "description": {
                "common": "insulin aspart, pramlintide. Mechanism: unspecified interaction mechanism. Contraindicated. Must be administered separately."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "insulin detemir",
            "description": {
                "common": "insulin detemir, pramlintide. Mechanism: unspecified interaction mechanism. Contraindicated. Must be administered separately."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "insulin glargine",
            "description": {
                "common": "insulin glargine, pramlintide. Mechanism: unspecified interaction mechanism. Contraindicated. Must be administered separately."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "insulin glulisine",
            "description": {
                "common": "insulin glulisine, pramlintide. Mechanism: unspecified interaction mechanism. Contraindicated. Must be administered separately."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "insulin lispro",
            "description": {
                "common": "insulin lispro, pramlintide. Mechanism: unspecified interaction mechanism. Contraindicated. Must be administered separately."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "insulin NPH",
            "description": {
                "common": "insulin NPH, pramlintide. Mechanism: unspecified interaction mechanism. Contraindicated. Must be administered separately."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "insulin regular human",
            "description": {
                "common": "insulin regular human, pramlintide. Mechanism: unspecified interaction mechanism. Contraindicated. Must be administered separately."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "acarbose",
            "description": {
                "common": "pramlintide, acarbose.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI nutrient absorption."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "aclidinium",
            "description": {
                "common": "pramlintide, aclidinium.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "anticholinergic/sedative combos",
            "description": {
                "common": "pramlintide, anticholinergic/sedative combos.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "atracurium",
            "description": {
                "common": "pramlintide, atracurium.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "atropine",
            "description": {
                "common": "pramlintide, atropine.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "atropine IV/IM",
            "description": {
                "common": "pramlintide, atropine IV/IM.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "belladonna alkaloids",
            "description": {
                "common": "pramlintide, belladonna alkaloids.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "belladonna and opium",
            "description": {
                "common": "pramlintide, belladonna and opium.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cisatracurium",
            "description": {
                "common": "pramlintide, cisatracurium.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cyclizine",
            "description": {
                "common": "pramlintide, cyclizine.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cyclobenzaprine",
            "description": {
                "common": "pramlintide, cyclobenzaprine.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "darifenacin",
            "description": {
                "common": "pramlintide, darifenacin.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dicyclomine",
            "description": {
                "common": "pramlintide, dicyclomine.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "diphenhydramine",
            "description": {
                "common": "pramlintide, diphenhydramine.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fesoterodine",
            "description": {
                "common": "pramlintide, fesoterodine.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "flavoxate",
            "description": {
                "common": "pramlintide, flavoxate.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "glycopyrrolate",
            "description": {
                "common": "pramlintide, glycopyrrolate.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "glycopyrrolate inhaled",
            "description": {
                "common": "pramlintide, glycopyrrolate inhaled.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "henbane",
            "description": {
                "common": "pramlintide, henbane.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "homatropine",
            "description": {
                "common": "pramlintide, homatropine.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hyoscyamine",
            "description": {
                "common": "pramlintide, hyoscyamine.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hyoscyamine spray",
            "description": {
                "common": "pramlintide, hyoscyamine spray.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "incobotulinumtoxinA",
            "description": {
                "common": "pramlintide, incobotulinumtoxinA. pharmacodynamic synergism. Avoid or Use Alternate Drug. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ipratropium",
            "description": {
                "common": "pramlintide, ipratropium.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "meclizine",
            "description": {
                "common": "pramlintide, meclizine.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methscopolamine",
            "description": {
                "common": "pramlintide, methscopolamine.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "miglitol",
            "description": {
                "common": "pramlintide, miglitol.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI nutrient absorption."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "onabotulinumtoxinA",
            "description": {
                "common": "pramlintide, onabotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "oxybutynin",
            "description": {
                "common": "pramlintide, oxybutynin.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "oxybutynin topical",
            "description": {
                "common": "pramlintide, oxybutynin topical.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "oxybutynin transdermal",
            "description": {
                "common": "pramlintide, oxybutynin transdermal.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pancuronium",
            "description": {
                "common": "pramlintide, pancuronium.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pralidoxime",
            "description": {
                "common": "pramlintide, pralidoxime.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "propantheline",
            "description": {
                "common": "pramlintide, propantheline.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rapacuronium",
            "description": {
                "common": "pramlintide, rapacuronium.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rocuronium",
            "description": {
                "common": "pramlintide, rocuronium.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "scopolamine",
            "description": {
                "common": "pramlintide, scopolamine.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "solifenacin",
            "description": {
                "common": "pramlintide, solifenacin.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tiotropium",
            "description": {
                "common": "pramlintide, tiotropium.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tolterodine",
            "description": {
                "common": "pramlintide, tolterodine.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trospium chloride",
            "description": {
                "common": "pramlintide, trospium chloride.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vecuronium",
            "description": {
                "common": "pramlintide, vecuronium.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "albiglutide",
            "description": {
                "common": "albiglutide, pramlintide.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Concurrent use may increase risk of hypoglycemia; monitor glucose levels."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aripiprazole",
            "description": {
                "common": "aripiprazole, pramlintide. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "asenapine",
            "description": {
                "common": "asenapine, pramlintide. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atazanavir",
            "description": {
                "common": "atazanavir decreases effects of pramlintide by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benztropine",
            "description": {
                "common": "pramlintide, benztropine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "darunavir",
            "description": {
                "common": "darunavir decreases effects of pramlintide by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dulaglutide",
            "description": {
                "common": "dulaglutide, pramlintide.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosamprenavir",
            "description": {
                "common": "fosamprenavir decreases effects of pramlintide by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "iloperidone",
            "description": {
                "common": "iloperidone, pramlintide. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indinavir",
            "description": {
                "common": "indinavir decreases effects of pramlintide by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin degludec",
            "description": {
                "common": "pramlintide, insulin degludec.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Pramlintide is indicated to be used in combination with insulin; however, pamlintide increases risk of insulin-induced hypoglycemia; reduce prandial insulin dose when initiating pramlintide."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin degludec/insulin aspart",
            "description": {
                "common": "pramlintide, insulin degludec/insulin aspart.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Pramlintide is indicated to be used in combination with insulin; however, pamlintide increases risk of insulin-induced hypoglycemia; reduce prandial insulin dose when initiating pramlintide."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin inhaled",
            "description": {
                "common": "pramlintide, insulin inhaled.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Pramlintide is indicated to be used in combination with insulin; however, pamlintide increases risk of insulin-induced hypoglycemia; reduce prandial insulin dose when initiating pramlintide."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "liraglutide",
            "description": {
                "common": "liraglutide, pramlintide.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Concurrent use may increase risk of hypoglycemia; monitor glucose levels."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lonapegsomatropin",
            "description": {
                "common": "lonapegsomatropin decreases effects of pramlintide by Other (see comment). Modify Therapy/Monitor Closely. \nComment: Closely monitor blood glucose when treated with antidiabetic agents. Lonapegsomatropin may decrease insulin sensitivity, particularly at higher doses. Patients with diabetes mellitus may require adjustment of their doses of insulin and/or other antihyperglycemic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lopinavir",
            "description": {
                "common": "lopinavir decreases effects of pramlintide by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lurasidone",
            "description": {
                "common": "lurasidone, pramlintide. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nelfinavir",
            "description": {
                "common": "nelfinavir decreases effects of pramlintide by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "olanzapine",
            "description": {
                "common": "olanzapine, pramlintide. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paliperidone",
            "description": {
                "common": "paliperidone, pramlintide. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quetiapine",
            "description": {
                "common": "quetiapine, pramlintide. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "risperidone",
            "description": {
                "common": "risperidone, pramlintide. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ritonavir",
            "description": {
                "common": "ritonavir decreases effects of pramlintide by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "saquinavir",
            "description": {
                "common": "saquinavir decreases effects of pramlintide by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "somapacitan",
            "description": {
                "common": "somapacitan decreases effects of pramlintide by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Growth hormone products may decrease insulin sensitivity, particularly at higher doses. Antidiabetic agents may require dose adjustment after initiating somapacitan. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tipranavir",
            "description": {
                "common": "tipranavir decreases effects of pramlintide by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trihexyphenidyl",
            "description": {
                "common": "pramlintide, trihexyphenidyl.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ziprasidone",
            "description": {
                "common": "ziprasidone, pramlintide. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Anorexia",
            "percent": null
        },
        {
            "name": "Severe hypoglycemia",
            "percent": null
        },
        {
            "name": "Inflicted injury",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Fatigue",
            "percent": null
        },
        {
            "name": "Abdominal pain",
            "percent": null
        },
        {
            "name": "Pharyngitis",
            "percent": null
        },
        {
            "name": "Cough",
            "percent": null
        },
        {
            "name": "Arthralgia",
            "percent": null
        },
        {
            "name": "Allergic reaction",
            "percent": null
        },
        {
            "name": "Injection site reactions",
            "percent": null
        },
        {
            "name": "Pancreatitis",
            "percent": null
        }
    ]
}